ProMIS Neurosciences News

ProMIS Neurosciences Advances Alzheimer's Treatment With PMN310

TipRanksApr 30 08:13 ET

ProMIS Neurosciences Publishes Study Highlighting Oligomer Selectivity and Benefit of Amyloid-Beta-Directed Antibodies

CAMBRIDGE, Massachusetts and TORONTO, Ontario, April 30, 2024 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (NASDAQ:PMN), a biotechnology company focused on the generation and development of antibody therapeutics

GlobeNewswireApr 30 07:00 ET

Why Ultragenyx Pharmaceutical Shares Are Trading Lower By Around 9%? Here Are Other Stocks Moving In Monday's Mid-Day Session

Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) fell sharply during Monday's session after the company revealed new data from the Phase 1/2 study of GTX-102 for Angelman syndrome, a genetic d

BenzingaApr 15 14:11 ET

Marinus Pharmaceuticals, Cartesian Therapeutics, Adial Pharmaceuticals Among Healthcare Movers

Seeking AlphaApr 15 10:00 ET

Dow Jumps Over 300 Points; Goldman Sachs Posts Upbeat Earnings

U.S. stocks traded higher this morning, with the Dow Jones index gaining more than 300 points on Monday. The Dow traded up 0.89% to 38,321.05 while the NASDAQ rose 0.70% to 16,288.03. The S&P 500 also

BenzingaApr 15 10:00 ET

ProMIS Neurosciences Publishes in the Journal of Biological Chemistry on the Interaction Between Pathogenic Proteins as a Treatment Target for ALS

CAMBRIDGE, Massachusetts and TORONTO, Ontario, April 09, 2024 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc.(NASDAQ:PMN), a biotechnology company focused on the generation and development of antibody therapeutics

GlobeNewswireApr 9 07:00 ET

ProMIS Neurosciences to Present in Upcoming Investor Conferences in April

CAMBRIDGE, Massachusetts and TORONTO, Ontario, April 04, 2024 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (NASDAQ:PMN), a biotechnology company focused on the generation and development of therapeutics targeting

GlobeNewswireApr 4 07:00 ET

Express News | ProMIS Neurosciences Q4 EPS $(0.09) Beats $(0.17) Estimate

Moomoo 24/7Apr 2 08:09 ET

ProMIS Neurosciences Net Loss For 2003 Narrows Vs a Year Earlier; Focus On First In-human Studies of Lead Product Candidate

ProMIS Neurosciences Inc. (Nasdaq: PMN and PMN.TO), a biotechnology company, on Monday said net loss was US$13.2 million for the full year ended December 31, 2023, compared to a net loss of $18.1 mill

MT NewswiresApr 1 16:41 ET

ProMIS Neurosciences Reports FY Results

Seeking AlphaApr 1 16:34 ET

ProMIS Neurosciences 2023 Loss/Shr $1.07 >PMN

ProMIS Neurosciences 2023 Loss/Shr $1.07 >PMN

Dow JonesApr 1 16:24 ET

ProMIS Neurosciences: Top-line Data From First-In-Human Phase 1A Trial of PMN310 to Treat Alzheimer's Disease on Track for Mid-2024 >PMN

ProMIS Neurosciences: Top-line Data From First-In-Human Phase 1A Trial of PMN310 to Treat Alzheimer's Disease on Track for Mid-2024 >PMN

Dow JonesApr 1 16:24 ET

ProMIS Neurosciences Brief: Says Strengthened Global Intellectual Property Portfolio

07:00 AM EDT, 03/11/2024 (MT Newswires) -- ProMIS Neurosciences Brief: Says Strengthened Global Intellectual Property Portfolio

MT NewswiresMar 11 07:00 ET

ProMIS Neurosciences Strengthens Global Intellectual Property Portfolio

CAMBRIDGE, Massachusetts and TORONTO, Ontario, March 11, 2024 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (NASDAQ:PMN), a biotechnology company focused on the generation and development of therapeutics targeting

GlobeNewswireMar 11 07:00 ET

ProMIS Neurosciences to Present at the 2024 BIO CEO & Investor Conference

CAMBRIDGE, Massachusetts and TORONTO, Ontario, Feb. 22, 2024 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (NASDAQ:PMN), a biotechnology company focused on the generation and development of therapeutics targeting toxic

GlobeNewswireFeb 22 07:00 ET

Express News | ProMIS Neurosciences Has Selected The Lead Vaccine Candidate, PMN400, Against Multiple Synucleinopathies Including Multiple System Atrophy, Parkinson's Disease And Lewy Body Dementia

Moomoo 24/7Jan 22 07:35 ET

ProMIS Neurosciences Achieves Milestone in Development of Therapeutic Alpha-Synuclein Vaccine

CAMBRIDGE, Massachusetts and TORONTO, Ontario, Jan. 22, 2024 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (NASDAQ:PMN), a biotechnology company focused on the generation and development of therapeutics targeting toxic

GlobeNewswireJan 22 07:00 ET

CRGE and LAES Among Mid-day Movers

Seeking AlphaJan 19 12:42 ET

Accelerate Diagnostics, Silk Road Medical Among Healthcare Movers

Seeking AlphaJan 19 09:59 ET

U.S. Shares Higher at Close of Trade; Dow Jones Industrial Average up 0.54%

InvestingJan 18 16:30 ET